Annotation Detail

Information
Associated Genes
MMP2
Associated Variants
MMP2 SERUM LEVELS
MMP2 SERUM LEVELS
Associated Disease
inflammatory breast carcinoma
Source Database
CIViC Evidence
Description
MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1156
Gene URL
https://civic.genome.wustl.edu/links/genes/3549
Variant URL
https://civic.genome.wustl.edu/links/variants/487
Rating
3
Evidence Type
Predictive
Disease
Inflammatory Breast Carcinoma
Evidence Direction
Supports
Drug
Bevacizumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26921265
Drugs
Drug NameSensitivitySupported
BevacizumabSensitivitytrue